trastuzumab deruxtecan + fluorouracil + durvalumab

This combination is an investigational multi-drug regimen under clinical evaluation for **HER2-expressing gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma**[1][2][7]. - **Trastuzumab deruxtecan** is an antibody-drug conjugate targeting HER2, consisting of a humanized anti-HER2 antibody linked to a topoisomerase I inhibitor (deruxtecan), resulting in direct cytotoxicity to HER2-positive cancer cells. - **Fluorouracil (5-FU)** is a cytotoxic antimetabolite that interferes with DNA synthesis, causing cell death by inhibiting thymidylate synthase[3][6]. - **Durvalumab** is an immune checkpoint inhibitor (monoclonal antibody) targeting programmed death ligand 1 (PD-L1), designed to enhance anti-tumor immune response[7]. The regimen is administered intravenously and is under investigation in phase 1/2 clinical trials for the first-line treatment of advanced/metastatic HER2-expressing gastric/GEJ cancers. No formal combination brand name exists. Key developers are AstraZeneca for durvalumab and Daiichi Sankyo for trastuzumab deruxtecan; both are directly involved in clinical development[7].

Brand names

Enhertu (for trastuzumab deruxtecan)None (no combination brand name identified)

Other names

T-DXd + 5-FU + durvalumabtrastuzumab deruxtecan + 5-fluorouracil + durvalumab